AUD 0.01
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 2.26 Million AUD | -23.26% |
2023 | 2.95 Million AUD | -72.51% |
2022 | 10.75 Million AUD | 25.41% |
2021 | 8.57 Million AUD | -32.51% |
2020 | 12.7 Million AUD | 120.94% |
2019 | 5.75 Million AUD | -12.73% |
2018 | 6.58 Million AUD | -20.69% |
2017 | 8.3 Million AUD | 20.25% |
2016 | 6.9 Million AUD | -20.01% |
2015 | 8.63 Million AUD | -20.08% |
2014 | 10.8 Million AUD | -15.21% |
2013 | 12.74 Million AUD | 0.0% |
2010 | 26.07 Million AUD | -17.0% |
2009 | 31.41 Million AUD | -14.31% |
2008 | 36.66 Million AUD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 2.65 Million AUD | 0.0% |
2024 FY | 2.26 Million AUD | -23.26% |
2024 Q4 | 2.26 Million AUD | 0.0% |
2024 Q1 | 2.65 Million AUD | -76.25% |
2023 Q2 | 4.3 Million AUD | 0.0% |
2023 Q1 | 4.3 Million AUD | -60.01% |
2023 FY | 2.95 Million AUD | -72.51% |
2023 Q3 | 2.95 Million AUD | -31.25% |
2023 Q4 | 11.16 Million AUD | 277.46% |
2022 FY | 10.75 Million AUD | 25.41% |
2022 Q3 | 10.75 Million AUD | -32.9% |
2022 Q4 | 10.75 Million AUD | 0.0% |
2022 Q1 | 16.02 Million AUD | 86.9% |
2022 Q2 | 16.02 Million AUD | 0.0% |
2021 Q4 | 8.57 Million AUD | 0.0% |
2021 Q1 | 10.76 Million AUD | 118.49% |
2021 Q2 | 10.76 Million AUD | 0.0% |
2021 Q3 | 8.57 Million AUD | -20.32% |
2021 FY | 8.57 Million AUD | -32.51% |
2020 Q4 | 4.92 Million AUD | 0.0% |
2020 Q3 | 4.92 Million AUD | -4.01% |
2020 FY | 12.7 Million AUD | 120.94% |
2020 Q2 | 5.13 Million AUD | 0.0% |
2020 Q1 | 5.13 Million AUD | -10.77% |
2019 FY | 5.75 Million AUD | -12.73% |
2019 Q4 | 5.75 Million AUD | 0.0% |
2019 Q2 | 4.78 Million AUD | 0.0% |
2019 Q1 | 4.78 Million AUD | -27.43% |
2019 Q3 | 5.75 Million AUD | 20.26% |
2018 FY | 6.58 Million AUD | -20.69% |
2018 Q2 | 8.37 Million AUD | 0.0% |
2018 Q1 | 8.37 Million AUD | 0.83% |
2018 Q3 | 6.58 Million AUD | -21.34% |
2018 Q4 | 6.58 Million AUD | 0.0% |
2017 Q2 | 5.85 Million AUD | 0.0% |
2017 FY | 8.3 Million AUD | 20.25% |
2017 Q4 | 8.3 Million AUD | 0.0% |
2017 Q1 | 5.85 Million AUD | -15.27% |
2017 Q3 | 8.3 Million AUD | 41.92% |
2016 Q2 | 8.13 Million AUD | 0.0% |
2016 Q4 | 6.9 Million AUD | 0.0% |
2016 Q3 | 6.9 Million AUD | -15.09% |
2016 FY | 6.9 Million AUD | -20.01% |
2016 Q1 | 8.13 Million AUD | -5.79% |
2015 FY | 8.63 Million AUD | -20.08% |
2015 Q3 | 8.63 Million AUD | -11.82% |
2015 Q2 | 9.79 Million AUD | 0.0% |
2015 Q4 | 8.63 Million AUD | 0.0% |
2015 Q1 | 9.79 Million AUD | -9.37% |
2014 FY | 10.8 Million AUD | -15.21% |
2014 Q4 | 10.8 Million AUD | 0.0% |
2014 Q1 | 11.16 Million AUD | -12.4% |
2014 Q3 | 10.8 Million AUD | -3.21% |
2014 Q2 | 11.16 Million AUD | 0.0% |
2013 Q4 | 12.74 Million AUD | 0.0% |
2013 FY | 12.74 Million AUD | 0.0% |
2013 Q1 | 13.96 Million AUD | 0.0% |
2013 Q2 | 13.96 Million AUD | 0.0% |
2013 Q3 | 12.74 Million AUD | -8.74% |
2010 FY | 26.07 Million AUD | -17.0% |
2010 Q4 | 26.07 Million AUD | 0.0% |
2009 Q4 | 31.41 Million AUD | 0.0% |
2009 FY | 31.41 Million AUD | -14.31% |
2008 Q4 | 36.66 Million AUD | 0.0% |
2008 FY | 36.66 Million AUD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AdAlta Limited | 5.57 Million AUD | 59.286% |
Acrux Limited | 8.96 Million AUD | 74.685% |
Race Oncology Limited | 20.22 Million AUD | 88.783% |
Biome Australia Limited | 8.27 Million AUD | 72.586% |
Botanix Pharmaceuticals Limited | 112.46 Million AUD | 97.982% |
BTC Health Limited | 5.14 Million AUD | 55.931% |
Chimeric Therapeutics Limited | 15.27 Million AUD | 85.144% |
CSL Limited | 56.93 Billion AUD | 99.996% |
Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 98.533% |
Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 99.018% |
EZZ Life Science Holdings Limited | 25.55 Million AUD | 91.12% |
Immutep Limited | 147.44 Million AUD | 98.461% |
Memphasys Limited | 12.43 Million AUD | 81.746% |
Neuren Pharmaceuticals Limited | 247.97 Million AUD | 99.085% |
Noxopharm Limited | 6.78 Million AUD | 66.552% |
Prescient Therapeutics Limited | 20.39 Million AUD | 88.874% |
Radiopharm Theranostics Limited | 72.03 Million AUD | 96.85% |
Starpharma Holdings Limited | 36.81 Million AUD | 93.837% |
Tissue Repair Ltd | 19.38 Million AUD | 88.298% |
Biotron Limited | 493.47 Thousand AUD | -359.8% |
Alterity Therapeutics Limited | 19.22 Million AUD | 88.197% |
Anatara Lifesciences Ltd | 1.67 Million AUD | -35.753% |
Bio-Gene Technology Limited | 3.15 Million AUD | 28.187% |
Zelira Therapeutics Limited | 5.18 Million AUD | 56.226% |
Patrys Limited | 4.16 Million AUD | 45.477% |
Orthocell Limited | 26.61 Million AUD | 91.475% |
Imugene Limited | 151.39 Million AUD | 98.501% |
PYC Therapeutics Limited | 91.23 Million AUD | 97.513% |
Proteomics International Laboratories Limited | 10.87 Million AUD | 79.136% |
Cynata Therapeutics Limited | 8.38 Million AUD | 72.95% |
Arovella Therapeutics Limited | 13.28 Million AUD | 82.92% |
Nanollose Limited | 241.95 Thousand AUD | -837.795% |
Invex Therapeutics Ltd | 6.12 Million AUD | 62.925% |
NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | 58.259% |
Amplia Therapeutics Limited | 14.84 Million AUD | 84.715% |
Island Pharmaceuticals Limited | 2.56 Million AUD | 11.522% |
Nyrada Inc. | 5.9 Million AUD | 61.59% |
Telix Pharmaceuticals Limited | 398.3 Million AUD | 99.43% |
Dimerix Limited | 32.07 Million AUD | 92.927% |
PharmAust Limited | 11.12 Million AUD | 79.604% |
AnteoTech Limited | 9.38 Million AUD | 75.813% |
Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 91.716% |
Recce Pharmaceuticals Ltd | 6.36 Million AUD | 64.378% |
Avecho Biotechnology Limited | 7.31 Million AUD | 69.0% |
Actinogen Medical Limited | 21.31 Million AUD | 89.353% |
Immuron Limited | 15.54 Million AUD | 85.408% |
Argenica Therapeutics Limited | 16.37 Million AUD | 86.146% |